We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid, Highly Accurate Test Developed to Detect Viruses

By LabMedica International staff writers
Posted on 16 Dec 2021
The rapid spread of viral infections demands early detection strategies to minimize proliferation of the disease. More...
A device has been developed that detects viruses in the body as fast as and more accurately than current, commonly used rapid detection tests.

The optical sensor device uses nanotechnology to accurately identify viruses in seconds from blood samples. The device works by using nano-scale patterns of gold that reflect back the signature of the virus it is set to detect in a sample of blood. Different viruses can be detected by using different DNA sequences that selectively target specific viruses.

Bioengineers from the University of Central Florida (Orlando, FL, USA), who developed the device, demonstrated a plasmonic biosensor to detect Dengue virus, a mosquito transmitted pathogen that causes Dengue fever, which was chosen as a model, via its nonstructural protein NS1 biomarker. The sensor is functionalized with a synthetic single-stranded DNA oligonucleotide and provides high affinity toward NS1 protein present in the virus genome.

The scientist reported that the device can tell with 95% accuracy if someone has a virus, a significant improvement over current rapid tests that experts warn could have low accuracy. Testing for viruses is important for early treatment and to help stop their spread. They demonstrated the detection of NS1 protein at a concentration of 0.1–10 μg/mL in bovine blood using an on-chip microfluidic plasma separator integrated with the plasmonic sensor which covers the clinical threshold of 0.6 μg/mL of high risk of developing Dengue hemorrhagic fever. The device closely matches the accuracy of the gold-standard PCR-based tests, but with nearly instantaneous results instead of results that take several days to receive.

Debashis Chanda, PhD, a Professor of Nanoscience Technology and senior author of the study, said, “The sensitive optical sensor, along with the rapid fabrication approach used in this work, promises the translation of this promising technology to any virus detection including COVID-19 and its mutations with high degree of specificity and accuracy. We have demonstrated a credible technique which combines PCR-like genetic coding and optics on a chip for accurate virus detection directly from blood.”

The authors concluded that the conceptual and practical demonstration shows the translation feasibility of these microfluidic optical biosensors for early detection of a wide range of viral infections, providing a rapid clinical diagnosis of infectious diseases directly from minimally processed biological samples at point of care locations. The study was originally published on September 8, 2021 in the journal Nano Letters.

Related Links:
University of Central Florida


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.